<?xml version="1.0" encoding="UTF-8"?>
<p>High levels of poor-neutralising prM antibodies are also found during secondary infection with 
 <italic>in vitro</italic> ADE activity [
 <xref rid="B65-vaccines-07-00203" ref-type="bibr">65</xref>,
 <xref rid="B89-vaccines-07-00203" ref-type="bibr">89</xref>]. Additionally, antibodies against NS1 are found during infection [
 <xref rid="B65-vaccines-07-00203" ref-type="bibr">65</xref>,
 <xref rid="B66-vaccines-07-00203" ref-type="bibr">66</xref>,
 <xref rid="B95-vaccines-07-00203" ref-type="bibr">95</xref>] and have been shown to enhance NS1â€²s complement activation activity and cross-react with platelets and endothelial cells. This may be an important contributor to vascular leakage and haemorrhaging [
 <xref rid="B96-vaccines-07-00203" ref-type="bibr">96</xref>,
 <xref rid="B97-vaccines-07-00203" ref-type="bibr">97</xref>,
 <xref rid="B98-vaccines-07-00203" ref-type="bibr">98</xref>,
 <xref rid="B99-vaccines-07-00203" ref-type="bibr">99</xref>,
 <xref rid="B100-vaccines-07-00203" ref-type="bibr">100</xref>], however, antibodies against NS1 have also been shown to reduce vascular leakage [
 <xref rid="B77-vaccines-07-00203" ref-type="bibr">77</xref>]. This may be explained by differences in the amounts or type of antibodies raised against NS1. A few antibodies have also been detected against other proteins, including non-structural [
 <xref rid="B101-vaccines-07-00203" ref-type="bibr">101</xref>,
 <xref rid="B102-vaccines-07-00203" ref-type="bibr">102</xref>].
</p>
